加载中

    Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy. Pellini Francesca,Granuzzo Eleonora,Urbani Silvia,Mirandola Sara,Caldana Marina,Lombardi Davide,Fiorio Elena,Mandarà Marta,Pollini Giovanni Paolo Breast care (Basel, Switzerland) Background:Male breast cancer (MBC) is a rare disease with a rising incidence trend. The major risk factors related to MBC are a positive family history of breast cancer (BC) and / mutations, which indicate a relevant genetic role. Methods:In this retrospective series, we enrolled 69 male patients presenting with male breast cancer (MBC) between 01/01/1992 and 31/12/2018, and 26 high-risk not-affected men presenting between 01/01/2016 and 31/12/2018. Participants' electronic clinical records were reviewed. Patients' data reported age at diagnosis, tumor characteristics, therapeutic management, and / status as well as a family history of breast, ovarian, or prostate cancer (PCa) in first-degree relatives. Results:We analyzed 69 MBC patients. Median age was 64 years. The majority of tumors diagnosed were of an early TNM stage. The most frequent histological subtype was invasive ductal carcinoma (76.7%). Hormone receptors were positive in >90% of MBC cases. Nearly all patients underwent modified radical mastectomy or total mastectomy. Adjuvant endocrine therapy was delivered in 59.4%. Among MBC-affected patients, we recorded a high percentage of a positive family history of BC. Mutational analysis for the / genes was performed in 17 MBC patients; 11.8% were carriers of pathogenic mutations. Among 26 healthy high-risk subjects included in this case series, 4 were mutation carriers and 9 were mutation carriers. Discussion:We evaluated the distribution of clinicopathological characteristics in MBC subjects and assessed the frequency of mutations in the genes in affected patients and healthy high-risk subjects, with the aim of proposing a surveillance program for BC and PCa. 10.1159/000501711
    Molecular Characterization and Mortality From Breast Cancer in Men. Massarweh Suleiman Alfred,Sledge George W,Miller Dave P,McCullough Debbie,Petkov Valentina I,Shak Steven Journal of clinical oncology : official journal of the American Society of Clinical Oncology Purpose Limited data exist on the molecular biology, treatment, and outcomes of breast cancer in men, and much of our understanding in this area remains largely an extrapolation from data in women with breast cancer. Materials and Methods We studied men and women with hormone receptor-positive breast cancer and the 21-gene Breast Recurrence Score (RS) results. Differences in clinical characteristics and gene expression were determined, and distribution of RS results was correlated with 5-year breast cancer-specific survival (BCSS) and overall survival. Results There were 3,806 men and 571,115 women. Men were older than women (mean age, 64.2 v 59.1 years; P < .001). RS < 18 predominated in both genders, but RS ≥ 31 was more frequent in men (12.4% v 7.4%; P < .001), as were very low scores (RS < 11; 33.8% v 22.1%; P < .001). Mean gene expression was higher in men for the estrogen receptor (ER), proliferation, and invasion groups. ER was lowest and progesterone receptor was highest in women younger than 50 years of age, with a progressive increase in ER with age. Men younger than 50 years of age had slightly lower ER and progesterone receptor compared with older men. Survival data were available from SEER for 322 men and 55,842 women. Five-year BCSS was 99.0% (95% CI, 99.3% to 99.9%) and 95.9% (95% CI, 87.6% to 98.7%) for men with RS < 18 and RS 18-30, respectively, and for women, it was 99.5% (95% CI, 99.4% to 99.6%) and 98.6% (95% CI, 98.4% to 98.8%), respectively. RS ≥ 31 was associated with an 81.0% 5-year BCSS in men (95% CI, 53.3% to 93.2%) and 94.9% 5-year BCSS (95% CI, 93.9% to 95.7%) in women. Five-year BCSS and overall survival were lower in men than in women. Conclusion This study reveals some distinctive biologic features of breast cancer in men and an important prognostic role for RS testing in both men and women. 10.1200/JCO.2017.76.8861
    ASO Author Reflections: Deescalating Therapy for Older Men with Early Estrogen Receptor Positive Breast Cancer. Perry Lauren M,Bateni Sarah B,Sauder Candice A M Annals of surgical oncology 10.1245/s10434-020-09357-x
    Male breast cancer: a nation-wide population-based comparison with female breast cancer. Lautrup Marianne D,Thorup Signe S,Jensen Vibeke,Bokmand Susanne,Haugaard Karen,Hoejris Inger,Jylling Anne-Marie B,Joernsgaard Hjoerdis,Lelkaitis Giedrius,Oldenburg Mette H,Qvamme Gro M,Soee Katrine,Christiansen Peer Acta oncologica (Stockholm, Sweden) OBJECTIVE:Describe prognostic parameters of Danish male breast cancer patients (MBCP) diagnosed from 1980-2009. Determine all-cause mortality compared to the general male population and analyze survival/mortality compared with Danish female breast cancer patients (FBCP) in the same period. MATERIAL AND METHODS:The MBCP cohort was defined from three national registers. Data was extracted from medical journals. Data for FBCP is from the DBCG database. Overall survival (OS) was quantified by Kaplan-Meier estimates. Standardized mortality ratios (SMRs) were calculated based on mortality rate among patients relative to the mortality rate in the general population. The association between SMR and risk factors were analyzed in univariate and multivariable Poisson regression models. Separate models for each gender were used for the analyses. RESULTS:We found a marked difference in OS for the two genders. For the total population of MBCP, 5- and 10-year survivals were 55.1% and 31.7%, respectively. For FBCP, the corresponding figures were 76.8% and 59.3%. Median age at diagnosis for FBCP was 61 years and 70 years for MBCP. By applying SMR, the difference in mortality between genders equalized and showed pronounced age-dependency. For males <40 years, SMR was 9.43 and for females 19.56 compared to SMR for males 80 + years (0.95) and females 80 + years (0.89). During the period 1980-2009, the risk of dying gradually decreased for FBCP (p < .0001). The risk 1980-1984 was 35% higher than 2005-2009 (RR 1.35). Although the risk of dying for MBCP was also lowest in 2005-2009, there was no clear tendency (p = .1439). The risk was highest in 1990-1994 (RR =2.48). CONCLUSION:We found better OS for FBCP than for MBCP. But SMR showed similar mortality rate for the two genders, except for very young FBCP, who had higher SMR. Furthermore, significantly improved survival over time for FBCP was observed, with no clear tendency for MBCP. 10.1080/0284186X.2017.1418088